T here is convincing evidence, based on animal and human experiments, population studies, and clinical trials, that cholesterol-lowering intervention is important in the treatment of patients with documented coronary heart disease (CHD). Nevertheless, inadequate attention has been paid to cholesterol lowering in patients with CHD, in part because of the emphasis previously placed on indexes of myocardial function as predictors of the course of coronary disease. ' On September 4-5, 1991, the American Heart Association and the National Heart, Lung, and Blood Institute cosponsored a meeting to discuss this issue. Experts in cardiology, lipidology, epidemiology, and health economics suggested approaches to cholesterol intervention in patients with established coronary disease. (The appendix is a list of the participants.) This report is not intended to preempt the recommendations to be developed by the new Adult Treatment Panel of the National Cholesterol Education Program (NCEP), which is being convened to update the existing cholesterol treatment guidelines for adults.
Current State of Affairs
There is considerable evidence indicating that reduction of low density lipoprotein cholesterol (LDL-C) levels is beneficial in preventing recurrent events in patients with established CHD. There is also evidence suggesting that increases in high density lipoprotein cholesterol (HDL-C) levels may likewise be beneficial in reducing the rate of recurrent events in these patients. Such evidence includes observations that LDL-C and HDL-C levels predict the risk of subsequent CHD death rates in both those with and those without established coronary heart disease (CHD). those that lower levels of LDL-C, will reduce the rate of both fatal and nonfatal events in those with established coronary disease. In addition, there is evidence that increasing HDL levels and lowering triglyceride levels may also be beneficial in these patients. 13 The absolute risk of myocardial infarction is much higher in those with established disease. Control groups in secondary prevention trials have experienced rates of infarction of 6% annually, compared with 1% in primary prevention trials.3 LDL-C lowering, then, has the potential to prevent many more events in a population with established disease than in one without. The reduction in recurrent coronary event rates by cholesterol lowering compares favorably with other medical therapies, including aspirin14 and 8-blocker,"5 in reducing subsequent events.
Cholesterol lowering is also of value in those who have undergone bypass surgery4 as well as in those who have undergone angioplasty,16 although the magnitude of the benefit after these procedures is still under investigation. If the effects of these invasive interventions are compared with cholesterol lowering, it is apparent that bypass surgery and angioplasty provide immediate patency and enhanced coronary blood flow but have uncertain effects on recurrent event rates and subsequent morbidity and mortality. Conversely, lowering of LDL-C levels does little to improve immediate coronary flow but substantially reduces the risk of subsequent coronary events, including both recurrent infarction and coronary death.
At a recent workshop on the issue of low cholesterol levels and total mortality, it was found that statistical confounding was a likely factor in the association between low cholesterol levels and certain diseases, including cancer of the lung, in observational studies. 17 No cause-and-effect relation has been established, and there is little evidence from clinical trials that cancer mortality is increased or, in fact, that the very low levels of cholesterol statistically associated with increased cancer risks are achievable in most patients with coronary heart disease.
In meta-analysis of primary prevention trials, excess mortality from violent or traumatic death, including suicides, homicides, and accidents, has been observed. 18 No such relation has been confirmed in meta-analysis of secondary prevention, nor has any cause-and-effect relation been established. Indeed, these effects are apparently unrelated to cholesterol lowering itself, because many of the patients who suffered violent or traumatic deaths were not undergoing cholesterol-lowering therapy at the time. 19 Some population studies indicate a relation between very low cholesterol levels and an increased risk of hemorrhagic stroke.20 Again, direct evidence of a causeand-effect relation is lacking.
The long-term safety of cholesterol lowering is the subject of continued investigation. The issue of low cholesterol levels and possible disease associations, however, is far less pressing in patients with established CHD. Over 80% of deaths in these patients are from CVD. The risk of death from CHD in such patients far outweighs any small theoretical risk from a low cholesterol level.
Based on several published studies of serial coronary angiography,4-8 there is general agreement that cholesterol lowering can slow, halt, or even reverse the progression of coronary atherosclerosis. Only one, the Program on the Surgical Control of the Hyperlipidemias (POSCH),8 is large enough to explore the relation between arrest of atherogenesis and event rates. Although little regression was observed in this study, arrest of progression was associated with a reduction in coronary events.
Lack of association of regression (as opposed to arrest of progression) with coronary events is not necessarily unexpected. While the most severe lesions demonstrate the most regression with cholesterol lowering, current evidence suggests it is not necessarily the most severe lesions that are ultimately responsible for coronary events. 21 Cost-effectiveness of cholesterol lowering in those without CHD is a matter of considerable debate when alteration of cholesterol levels, particularly with drugs, is considered in those free of clinical coronary disease. Analysis, however, indicates that cholesterol lowering is cost effective in patients with CHD. In those with hypercholesterolemia (cholesterol levels >250 mg/dl) and CHD who are less than 65 years old (men) or 55 years old (women), models suggest that cholesterol lowering actually saves money by eliminating the cost of subsequent events, including bypass surgery and angioplasty.22 Be Relatively little evidence directly addresses the value of cholesterol interventions in persons with CAD yet with these relatively low LDL-C levels. In the Cholesterol Lowering Atherosclerosis Study (CLAS), those with low cholesterol levels had the same degree of regression as those with higher cholesterol levels4; again, the implication is that there may be a susceptible population at particular risk. Several field studies are being conducted that will be helpful in further delineating the benefit of lowering LDL-C levels to < 130 mg/dl. At present, it is necessary to rely on a few regression studies for evidence of that benefit. Clearly, further research in this area is necessary, both to better identify persons who terol intervention in those without (by current definitions) significant hypercholesterolemia.
Future recommendations to lower LDL-C targets below current levels in those with established disease must take into account the necessity of completing that research. Recommendations should not, if possible, discourage participation in such clinical trials.
Which Circulating Lipid Fractions Should Be
Targets for Intervention?
Low Density Lipoprotein Cholesterol LDL-C lowering is the primary target of intervention. There is justification, based on both animal and human regression studies,4-8 for a target level of LDL-C .100 mg/dl in those with established disease, and, in fact, for selecting anyone with an LDL-C level above that (and with established CHD) for either diet therapy or a combination of diet and drug therapy. As noted, enthusiasm must be tempered with the understanding that the benefit of cholesterol lowering to that degree is not yet established.
The conventional sequence of diet therapy before drug therapy is appropriate for patients with coronary disease. Those with established coronary disease, however, may be motivated to try more stringent fatrestricted diets. A lower target LDL-C level, moreover, may require more frequent use of drug combinations. In this respect, combinations of bile acid sequestrants with any of the systemic lipid-lowering drugs are safe and quite effective. Combinations of two systemic drugs, while also efficacious, may increase the likelihood of toxicity.24 They should be used with both caution and careful monitoring, particularly for evidence of druginduced myopathy or hepatic dysfunction.
High Density Lipoprotein Cholesterol HDL-C and triglycerides are more problematic targets of therapy. In studies of the regression of coronary disease, regression was associated with both lowering of LDL-C levels and increases in HDL-C levels.4-8 There is strong evidence, moreover, from population studies that the HDL-C level is an important predictor of risk in patients with CHD.2 There is little to suggest, however, that in patients with isolated low HDL-C levels (without elevated triglyceride levels), HDL-C levels can be significantly increased with either diet or drug therapy. A reasonable approach is to attempt to increase HDL-C levels whenever possible, particularly when triglyceride levels are elevated, but to continue to regard lowering of LDL-C levels as the main objective of therapy.
Triglycerides. Considerable evidence links elevated triglyceride levels to CHD, particularly when associated with decreases in HDL-C levels, increases in LDL-C levels, or the presence of a particular form of small, dense LDL, which is thought to be particularly atherogenic. 13 Only one clinical trial, the Stockholm Prospective Study,25 demonstrated that lowering of triglyceride levels was associated with a decline in coronary events. That study did not independently examine the effect of changes in LDL-C or HDL-C levels. However, efforts to lower triglyceride levels, particularly with weight loss, diet, and exercise, are important in correcting associated lipoprotein abnormalities, including low HDL-C are susceptible and to determine the value of choleslevels and increased small, dense LDL.
In its 1988 Adult Treatment Panel Report,9 the NCEP endorsed the conclusions of the 1983 National Institutes of Health Consensus Conference,26 which recommended that drug therapy be considered in persons whose triglyceride levels were >250 mg/dl after diet therapy and who also have established CHD, low HDL-C levels, or high LDL-C levels. A recent review of this topic by an international panel recommended essentially the same approach but suggested lowering the triglyceride threshold to 200 mg/dl.13 The subject of elevated triglyceride and low HDL levels was considered by a consensus conference of the National Institutes of Health in February 1992 and is being considered by the new Adult Treatment Panel.
Which Other Lipoprotein Fractions Identify Those
Susceptible to Heart Disease? Measurement of circulating apolipoprotein levels may provide better predictors of coronary risk than more traditional measurements of LDL-C, HDL-C, and triglyceride levels. In particular, apolipoprotein B levels may predict risk even in the presence of normal cholesterol levels,27 although this greatly depends on how a normal cholesterol level is defined. Nevertheless, the lack of a sufficient epidemiological and clinical data base, plus the large coefficient of variation in the measurement of circulating apolipoprotein levels,28 limits their usefulness as parameters for either the selection of subjects for therapy or as targets for therapeutic intervention, and their routine use cannot currently be recommended.
In similar fashion, levels of lipoprotein a [Lp(a)], a strong predictor of coronary risk29 and a potentially powerful detector of persons who are susceptible, cannot currently be recommended for use in selecting patients for therapy. Such a recommendation awaits a better understanding of how to measure Lp(a), how to lower its levels, and what effect manipulation of its circulating levels has on coronary risk.
In summary, the lipoproteins currently targeted for intervention should remain the same. Lowering of LDL-C levels is most important, but in patients with CHD declines in triglyceride levels and increases in HDL-C levels may be sought whenever feasible. The achievement of the steps suggested above will require the endorsement and cooperation of several organizations, including the NCEP, the American Heart Association, and other major professional organizations, such as the American College of Cardiology, the American College of Physicians, and the American Academy of Family Physicians. The NCEP provides an important forum for the development of this cooperative effort. Efforts within and among individual organizations to further these goals should also be pursued.
